Browse Articles
Discover research articles across all indexed journals
Molecular mechanisms of mitochondrial dynamics
κ/β‐Ga <sub>2</sub> O <sub>3</sub> Type‐II Phase Heterojunction
Abstract Ultrawide‐bandgap gallium oxide (Ga 2 O 3 ) holds immense potential for crucial applications such as solar‐blind photonics and high‐power electronics. Although several Ga 2 O 3 polymorphs, i.e., α, β, γ, δ, ε, and κ phases, have been identified, the band alignments between these phases have been largely overlooked due to epitaxy challenges and inadvertent neglect. Despite having similar stoichiometry, heterojunctions involving different phases may exhibit band offsets. Here, β‐Ga 2 O 3 /κ‐Ga 2 O 3 ‐stacked “phase heterojunction” is demonstrated experimentally. This phase heterojunction has a sharp and well‐defined interface, and subsequent measurements reveal an unbeknown type‐II band alignment with significant valence/conduction band offsets of ≈0.65 eV/0.71 eV. This alignment is promising for self‐powered deep ultraviolet (DUV) signal detection, necessitating an internal electric field near the junction and matching the absorption properties for effective electron–hole separation. The fabricated phase heterojunction photodetector displays a responsivity of three orders of magnitude higher at 17.8 mA W −1 , with improved response times (rise time ≈0.21 s, decay time ≈0.53 s) under DUV illumination and without external bias in comparison to the bare β‐Ga 2 O 3 and κ‐Ga 2 O 3 photodetectors, confirming the strong interfacial electrical field. This study provides profound insight into Ga 2 O 3 /Ga 2 O 3 heterojunction interfaces with different polymorphs, allowing the use of phase heterojunctions to advance electronic device applications.
Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.
TPS850 Background: ctDNA can identify the earliest sign of relapse (MRD) after curative therapies with specificities of 93-100%, positive predictive values over 95%, and median lead times of 8-9 months before radiographic relapse. ctDNA has identified a "new stage" of high-risk patients (pts) with no evidence of disease radiographically (rNED) and MRD who lack treatment (tx) strategies as, traditionally, they wait for radiographic progression of disease (POD) before starting therapies. Treating MRD is a promising strategy supported by observational studies where ctDNA clearance is linked with improved survival and on-tx kinetics predict drug efficacy . We designed a pilot investigator-initiated trial to 1) determine the feasibility of using ctDNA as a rapid signal for positive therapeutic activity and 2) obtain pilot data on the efficacy of a novel combination therapy (atezolizumab [A] + bevacizumab [B]) in eradicating MRD in previously curatively treated pts with GI cancers. Methods: We will enroll 20 pts with any-stage cancers divided over 4 cohorts (n=5 colorectal [CRC], n=5 hepatocellular/biliary tract carcinoma, n=5 upper GI, n=5 pancreatic adenocarcinoma) who have a positive Signatera ctDNA test and rNED any time after completing standard curative therapies. Pts are treated with A 1200 mg IV + B 15 mg/kg IV on day 1 of a 21-day cycle for up to 1 year with imaging every 12 weeks and serial ctDNA testing every 3 weeks. Co-primary endpoints are rates of pt enrollment in 12 months and rates of ctDNA responses at a 12-week landmark after tx initiation. Pts with ctDNA POD (ctDNA doubling on each of 2 sequential tests, any rate of rise in 3 sequential tests, or radiographic relapse) will stop while those with ctDNA complete response (CR; clearance on 2 sequential tests + ongoing rNED) or ctDNA partial/stable response (PR; not ctDNA CR or POD + ongoing rNED) will continue tx. Each cohort's Bayesian predictive probability of positive therapeutic activity will be calculated. If at least 60% of a cohort experiences ctDNA CR, it will be expanded by 5 pts. This scenario is equivalent to Simon's 2-stage Minimax design testing a null hypothesis of 20% CR vs. an alternative hypothesis of at least 60% CR at 5% alpha with 80% power. If at least 5/10 pts in an expanded cohort experience ctDNA CR, this will generate interest in developing a larger confirmatory trial to evaluate pt survival outcomes with A+B and ctDNA as a surrogate for survival. Secondary endpoints are toxicity and enrollment barriers. Exploratory endpoints are associations between ctDNA conversion and disease-free survival, tumor whole exome sequencing data, and peripheral blood immune profiles collected at baseline and on tx. Enrollment began in Q1 2023, paused in 7/2023 due to funding changes, and re-opened 8/2024 with 5 patients enrolled currently (n=4 CRC, n=1 biliary). Clinical trial information: NCT05482516 .
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023.
450 Background: Tisle is an anti-PD-1 antibody. The combination of Tisle + XELOX/FP is a first-line treatment of AGC in China. Both irinotecan and paclitaxel have also shown antitumor activity in AGC. In this phase I/II study, we explore the safety, tolerability, and efficacy of Tisle + POFI as first-line treatment of HER-2 negative, pMMR AGC. Methods: In a phase I dose finding study using a standard 3+3 design, subjects received four escalating dose levels (dl) of irinotecan/paclitaxel (mg/m 2 ): 135/45 (dl #1), 150/45 (dl #2), 135/67.5 (dl #3), and 135/90 (dl #4) in combination with tisle 200 mg plus oxaliplatin 85 mg/m 2 , levoleucovorin 200 mg/m 2 , and 5-FU 2400 mg/m 2 for 46 hours every 2 weeks. Primary endpoints were safety, tolerability, and RP2D. Results: Fifteen subjects with treatment naïve AGC were enrolled (3 each in dl #1, dl #2, and dl #3 and 6 in dl #4). The median age was 65 years (range 36-72); 80% were male. Two subjects (13.3%) were diagnosed with GE junction cancer, 11 (73.3%) had undifferentiated disease, and 5 (33.3%) had liver metastasis. PD-L1 CPS scores were: 5 (n=5); 1 (n=1); and 0 (n=9). All subjects were evaluated for DLT. One DLT (grade 4 neutropenia) occurred within 28 days in dl #4. No maximum tolerated dose was reached; the RP2D was dl #4. As of 18th Sep 2024, confirmed objective response rate in 13 subjects with measurable disease was 100% (1 CR, 12 PR) per RECIST 1.1. Of the 2 subjects with non-measurable disease, one was a CR and the other was non-CR/non-PD. The median PFS was 10.51 (95% CI: 7.44, 13.58) months (versus 6.9 [5.7-7.2] months for ITT population for RATIONALE 305, ESMO 2023), the median DOR was 7.39 (95% CI: 5.34, 9.44) months, and the median OS was 14.75 (95% CI: 5.48, 24.02) months. The OS showed no significant differences between CPS ≥ 1 and CPS < 1. All subjects (100%) had AEs. Seven (n=7, 46.67%) of the 15 subjects reported grade ≥3 AEs, including neutropenia (n=7; 46.67%), leukopenia (n=3; 20%), anemia (n=2; 13.33%). Conclusions: Tisle+POFI was well tolerated and showed preliminary antitumor activity in AGC. A phase II study is ongoing. Clinical trial information: NCT05319639 .
Multi-site blinded validation of a deep learning approach for clinical-grade MSI/dMMR detection in colorectal cancer from H&E-stained pathology images.
44 Background: Testing for microsatellite instability (MSI) or mismatch repair deficiency (dMMR) is part of the diagnosis and clinical management of patients with colorectal cancer (CRC). Healthcare services recommend MSI or dMMR testing for all CRC patients to guide therapeutic choices and assist in identifying Lynch Syndrome. However, in clinical practice, high costs and the demand for timely test results, combined with the rising prevalence of CRC and a shrinking pathology workforce, present a barrier to universal adoption. This highlights the need for rapid and affordable alternatives. PANProfiler CRC (PPC) is a deep learning-based solution for detecting MSI/dMMR in CRC tumors that only requires whole slide images (WSIs) of haematoxylin and eosin (H&E)-stained tissue to provide test results. Using only WSIs, PPC offers an efficient alternative to standard testing. This study evaluates PPC's performance in a multi-site blinded setting. Methods: Blinded validation was performed using 3246 WSIs of H&E-stained CRC specimens. PPC provided outputs as "Stable", "Unstable", or "Indeterminate", with "Unstable" indicating dMMR or MSI-High, and "Stable" indicating proficient mismatch repair or non-MSI-High. "Indeterminate" was returned when PPC did not have a definitive result. PPC was evaluated by comparison to standard MSI/dMMR tests. Validation data spanned three cohorts from two sites (Table). St James’s University Hospital (SJUH), Leeds, UK, supplied Cohorts 1 and 2; Cohort 3 was sourced from Wales Cancer Biobank (WCB), UK. Blinded analysis was performed at SJUH. Results: Results are given (Table). PPC demonstrated an overall percent agreement of 93.91%, a positive percent agreement of 92.17%, and a negative percent agreement of 94.15%, returning a definitive result for 88.05% of WSIs. Conclusions: This real-world, multi-site, blinded validation study demonstrates PPC’s remarkable performance, comparable to standard tests for detecting MSI/dMMR in CRC, with high test replacement rates. In the clinical setting, PPC could significantly accelerate testing and enable timely delivery of stratified treatment plans. This accurate and cost-effective diagnostic solution promises to revolutionize MSI/dMMR testing in CRC. Blinded validation results of PPC with confidence intervals (CI) at 95%. Site Cohort Sample Size (Unstable; Stable) Overall Percent Agreement % (CI) Positive Percent Agreement % (CI) Negative Percent Agreement %(CI) Test Replacement Rate % SJUH 1 488 (78; 410) 92.79 (89.86-95.08) 90.16 (79.81-96.30) 93.24(90.11-95.62) 85.25 SJUH 2 2704 (318; 2386) 94.31(93.31-95.21) 92.31(88.48-95.18) 94.57(93.52-95.50) 88.42 WCB 3 54 (11; 43) 84.31 (71.41-92.98) 100.00(71.51-100.00) 80.00(64.35-90.95) 94.44 All 3246 (407; 2839) 93.91 (92.97-94.76) 92.17(88.82-94.78) 94.15(93.16-95.04) 88.05
Mechanism and regulation of kinesin motors
Zero‐Waste Polyanion and Prussian Blue Composites toward Practical Sodium‐Ion Batteries
AbstractClosed‐loop transformation of raw materials into high‐value‐added products is highly desired for the sustainable development of the society but is seldom achieved. Here, a low‐cost, solvent‐free and “zero‐waste” mechanochemical protocol is reported for the large‐scale preparation of cathode materials for sodium‐ion batteries (SIBs). This process ensures full utilization of raw materials, effectively reduces water consumption, and simplifies the operating process. Benefiting from the synergistic effect between the cubic Prussian blue analogs (c‐NFFHCF) and dehydrated polyanionic sulfates (m‐NFS), the generated composite exhibits promising wide‐temperature electrochemical performance and excellent practical application potential. The synergistic effect between m‐NFS and c‐NFFHCF in the composite is revealed through multiple in situ characterizations and density functional theory calculations. The proposed mechanochemical strategy can be scaled to a kilogram‐grade level, providing a sustainable method for the value‐added utilization of the by‐products during Prussian blue analogs synthesis, advancing the design of “zero‐waste” cathode materials for low‐cost practical SIBs.
Patient-reported outcomes in GI cancer: Leading change to meet the needs of the gastrointestinal cancer community.
813 Background: According to the World Health Organization International Agency for Research on Cancer, globally gastrointestinal (GI) cancers account for 1 in 4 cancer cases and 1 in 3 cancer deaths, with an estimated 4.8 million new cases and 3.4 million GI cancer deaths reported annually. Understanding the global burden of GI cancers and the importance of understanding the real-world impact of a GI cancer diagnosis, the GI Cancers Alliance (GICA) conducted a 12-month patient-reported outcomes (PRO) research initiative that included a workshop at the 2023 American Society of Clinical Oncology (ASCO) annual meeting. In addition, our PRO research was published in the Journal of Clinical Oncology (J Clin Oncol 42, 2024 suppl 3; abstr 731) with a poster presented at the 2024 ASCO Gastrointestinal Cancers Symposium. Methods: Based on our 2022-2023 PRO research of 1,122 patients highlighting the unmet needs and critical gaps in services of the GI cancers community, we developed a series of follow-up initiatives. Nutrition education 17%, biomarker/precision medicine education 19%, patient-centered care education 11% and caregiver support 16% were four of the highest levels of unmet need based on our global research. Subsequently, in 2023 we created the ‘GI Cancers Patient & Caregiver Advisory Board’ representing all GI cancers. The board hosts educational forums supporting patients and caregivers throughout the care continuum. Our pilot nutrition program launched at the 2024 ASCO annual meeting, consisting of in-person and online video components, and an extensive nutrition guide with recipes tailored for GI cancer patients. In 2024, we partnered with our gastric cancer advocates to develop ‘Test Your Biomarkers’ enhancing education and awareness of biomarker testing and precision medicine. Results: Implementing direct patient feedback from our published research, we are creating actionable solutions to unmet needs and gaps in services. Our ‘Patient & Caregiver Advisory Board’ continues to amplify the patient and caregiver voice participating in global engagement opportunities. GICA provided 10,000 nutrition guides to community oncology centers, and our online messaging reached 250,000 individuals across digital platforms and partner websites in the first three months from launch. In the first six months of the ‘Test Your Biomarkers’ campaign our messaging reached 1.7 million individuals across all digital platforms, campaign, and partner websites. Conclusions: Our PRO research provides the roadmap for new initiatives and programming to meet the needs of our GI cancer community. The GI Cancers Alliance will proceed to collaborate with our 100+ partner organizations to activate change by targeting the needs of our patient community while eliminating critical gaps in services. By doing so, we will continue to provide greater patient impact through the amplification of the patient voice.
Mortality and other outcomes of hospitalizations due to pancreatic cancer.
780 Background: Pancreatic cancer continues to be a highly fatal malignancy of the digestive system and imposes a significant financial strain on healthcare systems. Although it is often diagnosed incidentally, several risk factors have been identified, including smoking, family history, age, race, gender, and alcohol use. In this study, we aimed to examine inpatient outcomes and the healthcare burden of patients hospitalized with pancreatic cancer. Methods: Patients admitted to the hospital in 2019 and 2020 were identified using the Nationwide Inpatient Sample database and categorized into two groups based on the presence of a pancreatic cancer diagnosis (with relevant ICD-10 codes). To account for confounding factors, multivariate regression analysis was applied when calculating mortality. Statistical analyses were conducted to assess mortality rates, length of stay and hospital charges. Results: : A total of 74,584 patients met the inclusion criteria, with a mean age of 68.5 years. The majority were white (69%), while black patients made up 13% of the study population, and 49% were female (36,570 patients). Thrombosis (OR: 2.08, p < 0.001), age over 60 (OR: 1.22, p = 0.042), and being of black race (compared to white race, OR: 1.45, p = 0.001) were linked to higher mortality rates. Thrombosis was also associated with longer hospital stays (+1.9 days, p<0.001) and increased costs (+$16,003, p= 0.001). However, age over 60 (+0.26 days, p = 0.088; +$589, p = 0.833) and black race (+1.01 days, p< 0.001; +$1,493.7, p = 0.649) showed trends toward longer stays and higher costs, these were not statistically significant. On the other hand, pancreatic conditions such as chronic pancreatitis, pancreatic cysts, pseudocysts, or exocrine pancreatic insufficiency (OR: 0.589, p < 0.001), female gender (OR: 0.78, p = 0.002), and care at urban teaching facilities (OR: 0.37, p < 0.001) were associated with lower mortality. While female gender (+0.06 days, p=0.603; -$1699, p=0.448) did not significantly impact hospital length of stay or costs, pancreatic disease (+0.33 days, p = 0.031; +$10,826, p < 0.001) and being treated at urban teaching facilities (+1.8 days, p < 0.001; +$57,106, p < 0.001) were linked to longer stays and higher costs. Conclusions: Although some unmodifiable risk factors significantly increase mortality, thrombosis contributes not only to higher mortality but also to increased healthcare costs and longer hospital stays. However, it may be preventable with anticoagulation therapy. The inverse relationship between pancreatic disease and mortality could potentially be explained by more frequent imaging and earlier detection of malignancies in these patients. Analysis of factors influencing in-hospital mortality, length of hospital stay, and total charges in hospitalized patients. Data Mortality Length of hospital stay Total Charge Age>60 1.22(p=0.042) +0.26 days, p=0.088 $589, p=0.833 Race (black compared to white race) 1.45 (p=0.001) +1.01 days, p< 0.001 $1493.7, p=0.649 Female gender 0.78 (p=0.002) +0.06 days, p=0.603 -$1699, p=0.448 Treatment at urban teaching facility 0.37(p<0.001) +1.8 days, p<0.001 $57,106, p<0.001 Thrombosis 2.08(p<0.001) +1.9 days, p< 0.001 $16,003, p= 0.001 Pancreatic conditions 0.589(p<0.001) +0.33 days, p= 0.031 $10,826, p<0.001
Preclinical analysis and clinical validation to identify biomarkers for trifluridine/tipiracil (FTD/TPI) efficacy with or without bevacizumab in patients with metastatic colorectal cancer.
230 Background: We previously identified candidate biomarkers for FTD/TPI efficacy through preclinical and translational studies in patients with metastatic colorectal cancer (mCRC). Recent studies reported that FTD/TPI plus bevacizumab (BEV) improved survival compared to FTD/TPI alone. This study evaluated the clinical significance of these biomarkers in patients with refractory mCRC receiving either FTD/TPI plus BEV or FTD/TPI alone. Methods: Candidate biomarkers were selected based on our transcriptomic and cell biological analyses. We validated these biomarkers in mCRC patients treated with FTD/TPI plus BEV (cohort A) or FTD/TPI alone (cohort B). Blood samples were collected at baseline (BL), before the second cycle (2nd), and progressive disease (PD), with serum biomarker levels measured using ELISA. Change patterns were classified as ‘increased’ or ‘decreased’ from BL. To address the unbalanced distribution of baseline characteristics between cohorts, propensity score matching (PSM) was performed. Results: A total of 112 patients were included, with 34 in each cohort after PSM. Cohort A showed significantly longer overall survival (OS) (14.4 vs 6.2 months, HR 0.53, 95%CI: 0.30-0.93) and higher disease control (DC) (58.8 vs 34.4%, P=0.047) compared to cohort B. In univariate analysis, increased IL-8 or AREG at 2nd and increased IFI16 at PD were associated with poorer clinical outcomes. Grade ≥3 neutropenia (NEU) was linked to better survival in both cohorts. Multivariable analysis identified decreased AREG and Grade ≥3 NEU as better markers for progression-free survival and OS. OS was significantly longer in cohort A compared to B (12.8 vs 5.8 months, HR 0.43, 95%CI: 0.21-0.89) when IL-8 increased at 2nd. Cohort A also had longer OS compared to cohort B when EREG (12.8 vs 6.2 months, HR0.27, 95%CI: 0.11-0,65) or AREG (14.2 vs 9.7 months, HR 0.40, 95%CI: 0.17-0.95) decreased at 2nd. There was no significant interaction between the regimen and biomarkers (IL-8, EREG, and AREG) for OS. Conclusions: Our data suggest that AREG may serve as a prognostic marker for FTD/TPI efficacy. Changes in IL-8, EREG and AREG potentially contribute to the extended survival benefit of combining BEV with FTD/TPI.
Mechanisms and regulation of substrate degradation by the 26S proteasome
Relationship in gene amplification between <i>ERBB2</i> and other oncogenes: Implications for the therapeutic efficacy of trastuzumab (Tmab)-based chemotherapy (CTx) in HER2 positive gastric cancer.
468 Background: This study aimed to elucidate the molecular characteristics, focusing on the co-amplification of ERBB2 and other oncogenes, and to investigate their impact on treatment efficacy in HER2 positive GC. Methods: We conducted a phase 2 clinical trial (UMIN 00017602) evaluating the efficacy of S-1, oxaliplatin, and Tmab. Next-generation sequencing was performed using the TS-170 (Illumina). Results: 32 patients were enrolled, of whom 6 (19%) were IHC2+/FISH+. The median progression-free survival (PFS) and overall survival (OS) were 11.8 and 28.8 months. ERBB2 amplification with a cut-off value of 2.84 was present in 84.4% with a median copy number (CN) of 9.3 (range 2.4-76.6). Amplification of oncogenes other than ERBB2 , such as KRAS, FGFR2, MET, and CCNE1, was observed in 87.5%, and the median CN of the highest CNs among oncogenes other than ERBB2 was 7.8 (range 2.4-22.9). Eventually co-amplification was observed in 75%, and CNs of ERBB2 and other oncogenes showed an inverse correlation (r=0.345, p=0.058). In all tumors having ERBB2 CN ≥ 7.25 obtained by the ROC analysis, CN of ERBB2 was the highest among oncogenes ( ERBB2 dominant). Conversely, in 92% of the tumors having ERBB2 CNs < 7.25, CNs of oncogenes other than ERBB2 was higher than ERBB2 ( ERBB2 non-dominant) (p<0.001). Moreover, the highest CN of the oncogenes other than ERBB2 was higher in tumors with ERBB2 CNs < 7.25 than that with ERBB2 CNs ≥ 7.25 (median 12.6 vs 6.4 p=0.018). Patients with ERBB2 non-dominant tumors showed significantly shorter PFS (median 6.9 vs 17.0 months, HR 6.40, p=0.001) and OS (median 14.8 vs 35.5 months, HR 2.72, p=0.016) and numerically lower response rate (63.6 vs 90.0%, p=0.151) compared with those with ERBB2 dominant tumors. Conclusions: Most patients had co-amplification of ERBB2 and other oncogenes, and the dominance of oncogene amplification in the tumor was associated with treatment efficacy of Tmab-based CTs in HER2 positive GC. These results suggest that the dominance of oncogene CNs within the tumor may determine tumor drivenness and influence treatment efficacy.
A comprehensive molecular and clinical study of patients with young-onset CRC.
235 Background: Young-onset colorectal cancer (YO-CRC), defined as colorectal cancer diagnosed in individuals under 50 years of age, has emerged as a distinct clinical entity, often presenting at advanced stages. Despite the increasing incidence, molecular and clinical underpinnings of YO-CRC remain underexplored. This study aims to characterize the clinical and molecular features of YO-CRC and to evaluate their impact on OS. Methods: We retrospectively reviewed 110 patients diagnosed with YO-CRCfrom our institution’s molecular database. All patients underwent next-generation sequencing. Demographic, clinical, and molecular data, including age, gender, race, tumor location, cancer stage, and mutation status (KRAS, NRAS, BRAF, POLE, ERBB-2/HER2, microsatellite status), were collected by reviewing electronic medical records. For OS analysis, we focused on patients diagnosed with de novo Stage 4. Cox proportional hazards regression and Kaplan-Meier survival analysis were utilized to assess the association of these factors with OS, with statistical significance determined by a p-value threshold of <0.05. Results: Among 110 patients, N=44 (40%) presented with local disease (stage 1-3), while N=66 (60%) patients presented with de novo metastatic disease at the time of diagnosis. The median age at diagnosis was 44.5 years. The cohort consisted of 64% males and 36% females, with 84% of patients identified as White. Most tumors were left-sided (77%), including the distal colon/sigmoid (44%) and rectum (33%). KRAS and BRAF mutations were present 36% and 5.5%, respectively. ERBB-2/HER2 amplification and microsatellite instability were observed in 4.5% and 6.4% respectively. Tumor mutation burden (TMB) was <10 in 57% of patients, with 14% having TMB >20. CNV analysis revealed that 14% of patients had copy gains, 12% had concurrent gains/losses, and 31% had copy losses. Among the 66 Stage 4 patients, 44% had died by the time of analysis, with a median overall survival (OS) of 43.6 months (95% CI, 28.7 - not reached). KRAS mutation was found to be significantly associated with worse survival outcomes. Cox regression analysis reveals the prognostic significance of KRAS status, with a hazard ratio (HR) of 3.52 (95% CI: 1.59-7.76, P = 0.002 < 0.05), indicating a significantly higher risk of death for KRAS-mutant YO-CRC patients. Conclusions: KRAS mutations are a key prognostic factor in YO-CRC, highlighting the need for therapeutic need to improve outcomes in this high-risk group.
Frequency of surveillance CT scan ordering in patients with stage II/III colorectal cancer.
106 Background: Patients with stage II/III colorectal cancer (CRC) undergo surveillance CT scans to detect early asymptomatic oligometastatic spread, which can be treated with curative intent. However, randomized clinical trials show no difference in 5-year mortality in those that undergo low intensity surveillance (annual) compared a higher intensity strategy (every 6 months). In Ontario, the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) guidelines recommend surveillance CT scan for patients with stage II/III CRC every 12 months. We aimed to determine the frequency at which clinicians in our Ontario-based hospital system ordered surveillance CT scans for patients with stage II/III CRC. Methods: This single centre retrospective cohort study included all patients that underwent surgical resection for CRC from April 1, 2018 – March 31, 2019 at our academic tertiary care centre in Ontario, Canada. We excluded patients that were followed at an outside hospital, had stage IV disease, had disease recurrence, had a concurrent neoplasm, or did not have CRC. The primary outcome was the proportion of surveillance CT scans completed 10+ months after the previous scan. We also described sociodemographic and medical characteristics of included patients. Follow-up was until August 2023. Results: We included 200 patients. The median age was 62 years (IQR: 52-70), 48% (N=96) were female, the rectum was the most commonly involved disease site (43%, N=86), 38% (N=76) had stage III disease, and 54% (N=107) received adjuvant chemotherapy. A total of 1286 scans were ordered during the study period. Of these, 67% (N=860) were ordered as surveillance. Of these, 18% (n=155) were completed 10 months or longer from the previous scan. The median time interval between surveillance scans was 6.6 months (IQR: 5.9-7.9). Approximately 20% (n=137 of 630) of surveillance scans ordered by general surgeons were completed 10 months or longer from the previous scan, whereas only 9% (n=18 of 205) of scans ordered by medical oncologists were completed 10 months or longer from the previous scan. Less than 1% of surveillance scans (n=3) identified new metastatic disease. Conclusions: The minority of surveillance CT scans ordered in patients with stage II/III CRC in our hospital were timed in concordance with Ontario-based guidelines. Future studies should seek to standardize ordering habits such that they align with best practices.
Permeable and Durable Liquid‐Metal Fiber Mat as Implantable Physiological Electrodes with Long‐Term Biocompatibility
Abstract Implantable physiological electrodes provide unprecedented opportunities for real‐time and uninterrupted monitoring of biological signals. Most implantable electronics adopt thin‐film substrates with low permeability that severely hampers tissue metabolism, impeding their long‐term biocompatibility. Recent innovations have seen the advent of permeable electronics through the strategic modification of liquid metals (LMs) onto porous substrates. However, the durability of these electronics is limited by the inherent poor wettability of LMs, particularly within the intricate 3D skeleton of the porous substrate. Herein, the study reports a spatial wettability tuning strategy that solves the wettability issue of LMs within the porous substrates, enabling the LM physiological electrodes with high durability and long‐term biocompatibility. The study demonstrates the use of the electrodes as implantable neural interface to realize in vivo acquisition of electrocardiograph and electrocorticogram signals with long‐term biocompatibility and high signal‐to‐noise ratio. This work demonstrates a promising direction for rational design of durable implantable bioelectronics with long‐term biocompatibility.
Clinical outcomes of stereotactic body radiation therapy to the liver.
565 Background: Stereotactic body radiation therapy (SBRT) can accurately and effectively target liver lesions with an ablative dose. However, prior studies suggest that SBRT directed at tumors near the central hepatobiliary tract may lead to downstream toxicity including biliary stricture and impaired liver function. This study aims to evaluate clinical outcomes and hepatobiliary toxicities associated with SBRT to the liver. Methods: This retrospective study reviews 177 patients who received CT- or MR-guided SBRT to the liver at Dana-Farber Cancer Institute and Brigham and Women’s Hospital from 2010 to 2024. Patient demographics, treatment characteristics, and clinical outcomes were extracted from electronic medical records. Local control, regional control, and overall survival were assessed using Kaplan-Meier methods. Toxicity was evaluated by tracking the incidence of biliary stricture requiring intervention and Child-Pugh (CP) scores pre- and post-SBRT. Results: Of the 177 patients, 47 (26.6%) had primary disease and 130 (73.4%) had metastatic disease, with a median follow-up of 58.7 months. Among those with primary disease, 9 (19.1%) had post-SBRT local progression (median time to progression not reached, 95% CI: 47.3, NA) and 26 (55.3%) had regional progression (median time to progression of 20.5 months, 95% CI: 6.5, 58.1). Of patients with metastatic disease, 44 (33.8%) had local progression (median time to progression of 40.2 months, 95% CI: 23.0, NA) and 96 (73.8%) had regional progression (median time to progression of 5.9 months, 95% CI: 4.8, 9.3). Median overall survival post-SBRT was 34.6 months for primary disease (95% CI: 20.2, 57.7) and 23.6 months for metastatic disease (95% CI: 19.0, 28.8). 18 patients (10.1%) later developed biliary stricture requiring intervention (12.8% of primary disease and 9.2% of metastatic disease). Of the 119 patients with CP scores available, 59 patients (49.6%) had a maximum post-SBRT CP score increase of 2 or more (55.0% of primary disease, 46.8% of metastatic disease). Conclusions: This study demonstrates that SBRT is an effective treatment option for local control in the liver, with better survival and progression outcomes for primary disease compared to metastatic disease. Among potential post-SBRT toxicities, initial analysis indicates frequent increase in CP score and low incidence of biliary stricture requiring intervention. An ongoing analysis will explore whether the dose to central bile ducts correlates with late strictures and toxicities.
The role of artificial intelligence in colorectal cancer and polyp detection: A systematic review.
47 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Early detection and accurate diagnosis are essential for improving survival rates and optimizing therapeutic strategies. Recently, artificial intelligence (AI) technologies, such as machine learning algorithms, convolutional neural networks (CNNs), and computer-assisted diagnostic (CAD) systems, have significantly enhanced traditional diagnostic tools like colonoscopy and histopathology. This systematic review evaluates the current role of AI in CRC management, focusing on diagnostic improvements, predictive modeling, and outcome prediction. Methods: A comprehensive literature review was conducted using PubMed, Google Scholar, and MEDLINE using MeSH term to identify studies utilizing AI in CRC diagnosis and management, with a focus on diagnostic imaging, histopathological analysis, and predictive modeling. Studies were evaluated for the accuracy of AI-driven diagnostic systems and the predictive performance of AI models in clinical outcomes. Results: Out of 147 studies identified, 37 met the eligibility criteria for this review. AI tools such as CNNs, CAD systems, and EndoBRAIN showed high accuracy in CRC detection and polyp classification. Kudo et al. (2020) reported 98% CRC detection accuracy using EndoBRAIN. Blanes-Vidal et al. (2019) achieved 96.4% accuracy in polyp detection via DCNN. Additionally, Wang et al. (2019, 2020) demonstrated improved Adenoma Detection Rates (ADR) of 34.1% and 29.1%, respectively, using AI over traditional methods. For outcome prediction, AI models, including CNNs, predicted patient prognosis with reasonable accuracy, as highlighted by Skrede et al. (2020) with 76% accuracy in prognosis prediction. Conclusions: The systematic review and analysis of AI-assisted diagnostic modalities in colorectal cancer and polyp detection reveal promising results, with most models demonstrating high sensitivity, specificity, and accuracy. CNN-based models and CAD systems, in particular, show strong potential for improving detection rates and clinical outcomes in CRC screening. The studies included in this review demonstrate that AI can enhance diagnostic precision, particularly in identifying polyps and predicting clinical outcomes, with high validation rates. However, more external validation and long-term clinical studies are needed to fully establish the robustness of these AI tools in routine clinical practice.
Comparative efficacy of TAS-102 and chemotherapy rechallenge in the third-line setting and beyond in patients with advanced colorectal cancer: A retrospective study.
78 Background: The optimal approach to third line therapy for patients with metastatic colorectal cancer remains a subject of debate. Options include Trifluridine/Tipiracil (TAS-102), TAS-102 with bevacizumab, regorafenib, chemotherapy rechallenge with or without an anti-EGFR agent, or fruquintinib. This study aims to evaluate the efficacy of standard of care TAS-102, TAS-102 with bevacizumab, or regorafenib versus chemotherapy rechallenge in patients with metastatic colorectal cancer in the third line setting and beyond. Methods: We conducted a retrospective analysis of patients with metastatic colorectal cancer who received either TAS-102 with or without bevacizumab, regorafenib or chemotherapy rechallenge with or without an anti-EGFR agent between 2018 and 2023, at the Ministry of National Guard for Health Affairs in Riyadh, Saudi Arabia. Patients received such agents in the third line setting and beyond. Results: A total of 75 patients were included in this study, with 39 patients receiving TAS-102 with or without bevacizumab, or regorafenib, and 36 receiving chemotherapy rechallenge. The median patient age was 58 years (range 28-81), with the majority being males at 55%. Among the chemotherapy rechallenge group, 31% were treated with cetuximab and 6% had panitumumab rechallenge, some of which were guided by cell free DNA liquid biopsy testing. In the other group, 66% received regorafenib, 26% TAS-102 alone, and 8% TAS-102 with bevacizumab. At the time of analysis, 56% of patients had passed away. Median overall survival for patients who received TAS-102 with our without bevacizumab, and regorafenib in the third line setting was found to be 13.1 months. Whereas for patients who received chemotherapy rechallenge, their median overall survival was 19.5 months. Conclusions: Patients with metastatic colorectal cancer who received chemotherapy rechallenge in the third line setting survived longer compared with patients who received TAS-102 with or without bevacizumab, or regorafenib.
The role and regulation of integrins in cell migration and invasion
Long-course chemoradiation vs short-course radiation in total neoadjuvant therapy for rectal cancer: Propensity score case-matched analysis.
156 Background: Short-course radiotherapy (Short-TNT) is not widely used in the United States as part of total neoadjuvant therapy (TNT) for rectal cancer, due to concerns for lower tumor regression, increased local recurrence, and poorer quality of surgical specimens compared to long-course chemoradiotherapy (Long-TNT). However, there have been few studies that directly compared outcomes of Long-TNT versus Short-TNT. This study aimed to evaluate outcomes of Short-TNT versus Long-TNT. Methods: Consecutive patients with stage II-III rectal cancer who underwent TNT at an NCI-designated comprehensive cancer center from 2019 to 2022 were identified. Outcomes after Short-TNT and Long-TNT were compared using 1:1 propensity score matching. Results: Among 318 patients, 170 (85 Short-TNT, 85 Long-TNT) were eligible for the matched analysis (Table). The median follow-up was 31 months. The two groups were similar in tumor distance from anal verge (5cm vs. 6cm), clinical stage (stage III: 90.6% vs. 89.4%), radiologic high-risk features, and treatment sequence (induction chemotherapy: 30.5% vs. 28.2%). The Long-TNT was associate with a higher proportion of nonoperative management (38.8% vs. 24.7%, p=0.03). A local regrowth rate with long-TNT was not lower than short-TNT (39.4% vs. 28.6%, p=0.42). There were no differences in rates of clinical complete plus near-complete response (52.9% vs. 52.9%, p=1.00), overall complete response (pathologic plus sustained clinical complete response; 32.2% vs. 29.9%, p=0.74), and surgical outcomes including retrieved lymph nodes number (19 vs. 22, p=0.27), sphincter preservation (46.2% vs. 62.5%, p=0.10), distal margin (3cm vs. 3.5cm, p=0.77), CRM+ (83.8% vs. 3.1%, p=0.42) and postoperative complications (overall: 34.6% vs. 25.0%, p=0.14; ≥Grade3: 5.8% vs. 9.4%, p=0.60). Conclusions: Short-TNT had a comparable overall complete response rate with equivalent surgical outcomes to Long-TNT. Short-TNT should be revisited in the US as a viable alternative TNT strategy both for nonoperative management and for treatment of locally advanced rectal cancer. Propensity score case-matched analysis. Outcomes Total (n=170) Long-TNT (n=85) Short-TNT (n=85) p value Clinical complete/near complete response, number (%) 90 (52.9) 45 (52.9) 45 (52.9) 1.00 Non-operative management, number (%) 54 (31.8) 33 (38.8) 21 (24.7) 0.03 Overall complete response, number (%)* 54 (31.0) 26 (30.6) 28 (32.9) 0.74 Surgical outcomes Surgery (n=116) Surgery after Long-TNT (n=52) Surgery after Short-TNT (n=64) Sphincter-preserving surgery, number (%) 64 (55.2) 24 (46.2) 40 (62.5) 0.10 Circumferential resection margin +, number (%) 4 (3.4) 2 (3.8) 2 (3.1) 0.42 Distal margin, cm (range) 3.4 (0.1-12) 3 (0.2-6.5) 3.5 (0.1-12) 0.77 Major complications (≥Grade3), number (%) 9 (7.8) 3 (5.8) 6 (9.4) 0.60 *Pathologic + sustained clinical complete response.